RxDoctor Payments Data

Nathan Littlejohn, MD

Urology · Hot Springs, ARNPI 1215370861

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $10,729 of the $17,561 with a category attached, or 61.1%. It is spread thinly across 39 manufacturers, the largest accounting for just 20.4%. Reporting peaked in 2021 at $5,616 and has fallen 80.3% since, to $1,105 in 2025.

$17,561in general payments, 2019–2025

Across 447 payments — averaging $39.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$4K
  • Intuitive Surgical$3K
  • Axonics, Inc.$3K
  • Medtronic$2K
  • Teleflex LLC$1K
  • Procept Biorobotics Corporation$832
  • plus $4K from 33 others

What the payments were for

  • Speaking & faculty fees$2952%
  • Travel & lodging$3,53620%
  • Food & beverage$10,72961%
  • Education$3,00017%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,561 in reported general payments places this provider in the 75th percentile of 88 urology providers in Arkansas.

See all urology providers in Arkansas

Medicare billing

Part B allowed, 2024
$346,431
Medicare patients
841
Services billed
7,656

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron108$65,548
OrgovyxRelugolix24$62,464
GemtesaVibegron85$47,695
Tamsulosin Hcl546$5,701
Methenamine Hippurate93$5,074
Estradiol52$3,650
Trospium Chloride31$3,095
Oxybutynin Chloride ErOxybutynin Chloride193$2,986
Finasteride168$2,025
Silodosin31$1,652
Solifenacin Succinate62$1,639
Testosterone Cypionate45$1,060
Potassium Citrate ErPotassium Citrate16$864
Alfuzosin Hcl ErAlfuzosin Hcl47$776
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav75$475

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$508$110,158109 claims
Astellas Pharma US IncMyrbetriq$217$65,548108 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 88 urology providers in Arkansas.

Other urology in Hot Springs

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →